Cognition Therapeutics (CGTX) CEO buys 9,175 open-market shares

Rhea-AI Filing Summary

Cognition Therapeutics Inc CEO and President Lisa Ricciardi reported an open-market purchase of 9,175 shares of common stock at $1.10 per share on April 16, 2026. After this transaction, she directly holds 1,715,851 shares and indirectly holds 38,851 shares through her spouse.

Insider Trade Summary

Net Buyer: 9,175 shares ($10,093)

Net Buy 2 txns

Insider Ricciardi Lisa

Role CEO & President

Bought 9,175 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	9,175	$1.10	$10K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,715,851 shares (Direct, null); Common Stock — 38,851 shares (Indirect, By Spouse)

Footnotes (1)

Key Figures

Shares purchased: 9,175 shares Purchase price: $1.10 per share Direct holdings after transaction: 1,715,851 shares +1 more

4 metrics

Shares purchased 9,175 shares Open-market purchase of common stock on April 16, 2026

Purchase price $1.10 per share Price for 9,175 common shares bought by CEO

Direct holdings after transaction 1,715,851 shares Common stock directly owned after April 16, 2026 purchase

Indirect holdings by spouse 38,851 shares Common stock reported as indirectly owned "By Spouse"

Key Terms

open-market purchase, indirect ownership, transaction code "P", Common Stock

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

""ownership_type": "indirect""

transaction code "P" financial

"transaction_code": "P""

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ricciardi Lisa

(Last) (First) (Middle)

C/O COGNITION THERAPEUTICS INC

2500 WESTCHESTER AVE.

(Street)

PURCHASE NEW YORK 10577

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/16/2026		P		9,175	A	$1.1	1,715,851	D
Common Stock								38,851	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lisa Ricciardi	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CGTX CEO Lisa Ricciardi report?

Lisa Ricciardi reported buying 9,175 shares of Cognition Therapeutics common stock at $1.10 per share. The transaction was an open-market purchase on April 16, 2026, indicating she increased her direct equity stake in the company.

How many Cognition Therapeutics (CGTX) shares does the CEO now own?

Following the reported transaction, Lisa Ricciardi directly owns 1,715,851 shares of Cognition Therapeutics common stock. She also has indirect ownership of 38,851 shares held by her spouse, as disclosed in the Form 4 filing.

What price did the CGTX CEO pay for the recently purchased shares?

Lisa Ricciardi purchased 9,175 shares of Cognition Therapeutics common stock at $1.10 per share. This open-market purchase price reflects what she paid on April 16, 2026, according to the Form 4 insider transaction report.

Are any of the CGTX CEO’s Cognition Therapeutics shares held indirectly?

Yes. In addition to her direct holdings, 38,851 shares of Cognition Therapeutics common stock are reported as owned indirectly "By Spouse". This means those shares are held in her spouse’s name but disclosed as part of her overall beneficial ownership.

What type of transaction code is shown for the CGTX CEO’s share purchase?

The Form 4 lists transaction code "P" for Lisa Ricciardi’s trade, which denotes a purchase in an open market or private transaction. This confirms the filing treats the 9,175-share transaction as an open-market buy order.